These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26176225)

  • 1. Pretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers.
    Uno K; Yoshizaki K; Iwahashi M; Yamana J; Yamana S; Tanigawa M; Yagi K
    PLoS One; 2015; 10(7):e0132055. PubMed ID: 26176225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
    Kojima T; Yabe Y; Kaneko A; Hirano Y; Ishikawa H; Hayashi M; Miyake H; Takagi H; Kato T; Terabe K; Wanatabe T; Tsuchiya H; Kida D; Shioura T; Funahashi K; Kato D; Matsubara H; Takahashi N; Hattori Y; Asai N; Ishiguro N
    Mod Rheumatol; 2013 Sep; 23(5):977-85. PubMed ID: 23099471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab.
    Hirata S; Marotta A; Gui Y; Hanami K; Tanaka Y
    Arthritis Res Ther; 2015 Oct; 17():280. PubMed ID: 26449724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.
    Reiss WG; Devenport JN; Low JM; Wu G; Sasso EH
    Rheumatol Int; 2016 Feb; 36(2):295-300. PubMed ID: 26026604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.
    Tuckwell K; Gabay C; Sornasse T; Laubender RP; Wang J; Townsend MJ
    Adv Rheumatol; 2019 Dec; 59(1):54. PubMed ID: 31801637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
    Kizaki K; Yamashita F; Hayashi T; Funakoshi N
    Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
    Kim SK; Choe JY; Park SH; Lee H
    Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
    Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Origuchi T; Ida H; Eguchi K
    Mod Rheumatol; 2010 Feb; 20(1):40-5. PubMed ID: 19802651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study.
    Okano T; Inui K; Tada M; Sugioka Y; Mamoto K; Wakitani S; Koike T; Nakamura H
    Rheumatol Int; 2016 Mar; 36(3):349-57. PubMed ID: 26438386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis.
    Aizu M; Mizushima I; Nakazaki S; Nakashima A; Kato T; Murayama T; Kato S; Katsuki Y; Ogane K; Fujii H; Yamada K; Nomura H; Yachie A; Yamagishi M; Kawano M
    Mod Rheumatol; 2018 Jul; 28(4):592-598. PubMed ID: 28880691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
    Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A
    Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade.
    Gualtierotti R; Ingegnoli F; Griffini S; Grovetti E; Meroni PL; Cugno M
    Clin Exp Rheumatol; 2016; 34(3):451-8. PubMed ID: 27086948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis.
    Fujimoto M; Serada S; Suzuki K; Nishikawa A; Ogata A; Nanki T; Hattori K; Kohsaka H; Miyasaka N; Takeuchi T; Naka T
    Arthritis Rheumatol; 2015 May; 67(8):2056-60. PubMed ID: 25917892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A
    Kato M; Kaneko Y; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Nagasawa H; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Yokota I; Atsumi T; Takeuchi T
    Mod Rheumatol; 2020 May; 30(3):442-449. PubMed ID: 31106666
    [No Abstract]   [Full Text] [Related]  

  • 18. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker.
    Hwang YG; Balasubramani GK; Metes ID; Levesque MC; Bridges SL; Moreland LW
    Arthritis Res Ther; 2016 May; 18(1):108. PubMed ID: 27188329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.